ArticleJournal of neurotrauma2012
CD11d Antibody Treatment Improves Recovery in Spinal Cord-Injured Mice.
Article in Journal of neurotrauma, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications.Antibody therapeutics · 2025Article
- Evolving insights on the role of microglia in neuroinflammation, plasticity, and regeneration of the injured spinal cord.Frontiers in immunology · 2025Review
- Role of dendritic cells in spinal cord injury.CNS neuroscience & therapeutics · 2024Review
- Modulating neuroinflammation through molecular, cellular and biomaterial-based approaches to treat spinal cord injury.Bioengineering & translational medicine · 2023Review
- Immunomodulatory Strategies for Spinal Cord Injury.Biomedical journal of scientific & technical research · 2022Article
- Immune response following traumatic spinal cord injury: Pathophysiology and therapies.Frontiers in immunology · 2022Review
- Engineered extracellular vesicles derived from primary M2 macrophages with anti-inflammatory and neuroprotective properties for the treatment of spinal cord injury.Journal of nanobiotechnology · 2021Article
- β2 Integrin CD11d/CD18: From Expression to an Emerging Role in Staged Leukocyte Migration.Frontiers in immunology · 2021Review
- Integrin αDβ2 influences cerebral edema, leukocyte accumulation and neurologic outcomes in experimental severe malaria.PloS one · 2019Article
- Spinal Cord Injury Scarring and Inflammation: Therapies Targeting Glial and Inflammatory Responses.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- The Biology of Regeneration Failure and Success After Spinal Cord Injury.Physiological reviews · 2018Review
- Complement Receptors in Myeloid Cell Adhesion and Phagocytosis.Microbiology spectrum · 2016Review
- Rat models of spinal cord injury: from pathology to potential therapies.Disease models & mechanisms · 2016Review
- Reducing neuroinflammation by delivery of IL-10 encoding lentivirus from multiple-channel bridges.Bioengineering & translational medicine · 2016Article
- Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury.Cells, tissues, organs · 2016Review
- Serotonergic transmission after spinal cord injury.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion.Journal of neuroinflammation · 2013Article
- Complement activation in the injured central nervous system: another dual-edged sword?Journal of neuroinflammation · 2012Review
- A sulfated carbohydrate epitope inhibits axon regeneration after injury.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Acute administration of a monoclonal antibody (mAb) raised against the CD11d subunit of the leukocyte CD11d/CD18 integrin after spinal cord injury (SCI) in the rat greatly improves neurological outcomes. This has been chiefly attributed to the reduced infiltration of neutrophils into the injured spinal cord in treated rats. More recently, treating spinal cord-injured mice with a Ly-6G neutrophil-depleting antibody was demonstrated to impair neurological recovery. These disparate results could be due to different mechanisms of action utilized by the two antibodies, or due to differences in the inflammatory responses between mouse and rat that are triggered by SCI. To address whether the anti-CD11d treatment would be effective in mice, a CD11d mAb (205C) or a control mAb (1B7) was administered intravenously at 2, 24, and 48 h after an 8-g clip compression injury at the fourth thoracic spinal segment. The anti-CD11d treatment reduced neutrophil infiltration into the injured mouse spinal cord and was associated with increased white matter sparing and reductions in myeloperoxidase (MPO) activity, reactive oxygen species, lipid peroxidation, and scar formation. These improvements in the injured spinal cord microenvironment were accompanied by increased serotonin (5-HT) immunoreactivity below the level of the lesion and improved locomotor recovery. Our results with the 205C CD11d mAb treatment complement previous work using this anti-integrin treatment in a rat model of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.